TRPV4 is a Prognostic Biomarker That Correlates With the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs

doi:10.21203/rs.3.rs-383566/v1

Download PDF

Primary research

TRPV4 is a Prognostic Biomarker That Correlates With the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs

https://doi.org/10.21203/rs.3.rs-383566/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted 12 Apr, 2021

You are reading this latest preprint version

Background: Transient receptor potential cation channel subfamily V member 4 (TRPV4) has been reported to regulate tumor progression in many tumor types. However, its association with the tumor immune microenvironment remains unclear.

Methods: TRPV4 expression was assessed using data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) database. The clinical features and prognostic roles of TRPV4 were assessed using TCGA cohort. Gene set enrichment analysis (GSEA) of TRPV4 was conducted using the R package clusterProfiler. We analyzed the association between TRPV4 and immune cell infiltration scores of TCGA samples downloaded from published articles and the TIMER2 database.

Results: TRPV4 was highly expressed and associated with worse overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) in colon adenocarcinoma (COAD) and ovarian cancer. Furthermore, TRPV4 expression was closely associated with immune regulation-related pathways. Moreover, tumor-associated macrophage (TAM) infiltration levels were positively correlated with TRPV4 expression in TCGA pan-cancer samples. Immunosuppressive genes such as PD-L1, PD-1, CTLA4, LAG3, TIGIT, TGFB1, and TGFBR1 were positively correlated with TRPV4 expression in most tumors.

Conclusions: Our results suggest that TRPV4 is an oncogene and a prognostic marker in COAD and ovarian cancer. High TRPV4 expression is associated with tumor immunosuppressive status and may contribute to TAM infiltration based on TCGA data from pan-cancer samples.

Cancer Biology

TRPV4

tumor immune microenvironment (TIME)

pan-cancer

tumor immunosuppressive status

tumor-associated macrophage (TAM)

TRPV4 is a broadly expressed polymodally activated ion channel. It is reported to be involved in tumor progression in several tumor types, playing different or even opposite roles therein. For example, overexpression of TRPV4 promotes epithelial to mesenchymal transition in breast cancer cells [1]. TRPV4 also promotes metastasis of endometrial cancer cells by regulating the RhoA/ROCK1 pathway[2]. In contrast, TRPV4 activation inhibits glioma progression [1]. Despite these reports, the role of TRPV4 in most tumor types remains unclear.

A number of studies indicate that the tumor immune microenvironment (TIME) has clinicopathological significance in predicting therapeutic effect and prognosis in tumor patients[3-5]. It has been confirmed that solid tumors are composed of malignant, non-malignant, hematopoietic, and mesenchymal cells. Among the non-malignant cells, tumor-associated macrophages (TAMs) play an essential role in promoting tumor progression [6, 7]. High TAM levels in tumor tissues influence the immune escape status of tumors, rendering immunotherapy ineffective[8]. Thus, targeting genes that promote TAM infiltration may increase the sensitivity of immunotherapy.

In our study, we assessed TRPV4 expression using data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) database and found that TRPV4 was differentially expressed in 25 tumor types. Furthermore, in patients with colon adenocarcinoma (COAD) or ovarian cancer, high TRPV4 expression was associated with worse overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI). TRPV4 is predicted to influence immune regulation-related pathways. We further assessed the association between TRPV4 expression and immune cell infiltration scores and immunosuppressive genes in TCGA pan-cancer samples and found that TRPV4 expression was positively correlated with TAM infiltration and immunosuppressive genes such as PD-L1, PD-1, CTLA4, LAG3, TIGIT, TGFB1, and TGFBR1 in pan-cancer samples.

Our study explored the role of TRPV4 in TCGA pan-cancer and further highlight a potential function whereby TRPV4 may regulate TAM infiltration and tumor immunosuppressive microenvironment.

Data sources

TCGA and GTEx expression and clinical data were obtained from the UCSC Xena database (https://xenabrowser.net/datapages/). DNA copy number and methylation data were downloaded from the cBioPortal database (https://www.cbioportal.org/). The IC₅₀ values of drugs and gene expression profiles in the relative cell lines were downloaded from the Genomics of Drug Sensitivity in Cancer (GDSC) database (https://www.cancerrxgene.org/).

Data analysis tools

Copy number alteration (CNA) and mutation status of TRPV4 in TCGA pan-cancer samples were analyzed using the cBioPortal database. The TIMER2 (http://timer.cistrome.org/) database was used to analyze the correlation between immune cell infiltration and TRPV4. R packages ggplot2, ggpubr, and gridExtra were used to draw TRPV4 expression patterns in the R software (3.6.2). R packages survival and survminer were used to perform Kaplan-Meier survival analysis and univariate Cox regression analysis, respectively. Gene set enrichment analysis (GSEA) was performed using the R package clusterProfiler.

TIME analysis

Immune cell infiltration correlation analysis was performed using two methods: 1) the TIMER2 database was used to analyze the correlation between immune cell infiltration and TRPV4; and 2) the immune cell infiltration scores of TCGA pan-cancer samples were downloaded from the ImmuCellAI database (http://bioinfo.life.hust.edu.cn/web/ImmuCellAI/) to perform the correlation analysis. To compare levels of immune cell infiltration, tumor samples from each tumor type were divided into two groups (high-TRPV4 and low-TRPV4 groups) according to the median expression of TRPV4 in each tumor types.

Statistical analysis

Data are presented as the mean ± SD. Differences between the groups were analyzed using Student’s t-test. Statistical analysis was performed using R 3.6.2. P < 0.05 (two-tailed) was considered statistically significant: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

TRPV4 expression in pan-cancer

We first assessed TRPV4 expression in tumor tissue samples from TCGA and normal tissue samples from TCGA and the GTEx database. We found that TRPV4 was overexpressed in 19 cancer types, namely, bladder urothelial carcinoma (BLCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBCL), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), acute myeloid leukemia (LAML), brain low-grade glioma (LGG), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), testicular germ cell tumors (TGCTs), thymoma (THYM), uterine corpus endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS). In contrast, low TRPV4 expression was observed in only six cancer types, namely, adrenocortical carcinoma (ACC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), and thyroid carcinoma (THCA) (Figure 1A). For tumor tissue data mined from TCGA, TRPV4 expression was highest in kidney renal clear cell carcinoma (KIRC) and lowest in LAML (Figure 1B). For normal tissue data from the GTEx database, the highest TRPV4 expression was observed in the salivary gland and prostate, while the lowest expression was detected in bone marrow (Figure 1C).

For paired tumors and normal tissues in TCGA, TRPV4 was overexpressed in BLCA, CESC, CHOL, COAD, ESCA, LUSC, pheochromocytoma/paraganglioma (PCPG), and STAD (Figure 2A-H), while low TRPV4 expression was observed in LIHC, PRAD, breast invasive carcinoma (BRCA), kidney chromophobe (KICH), and KIRP (Figure 2I-M).

TRPV4 alteration analysis

We further explored TRPV4 gene alterations in TCGA pan-cancer samples using cBioPortal and observed that patients with UCEC and ACC presented high gene alteration frequencies, including mutations and amplifications (Figure 3A). In addition, we downloaded copy number and methylation data for TRPV4 and performed a correlation analysis. The results revealed that copy number values were positively correlated with TRPV4 expression (Figure 3B), while methylation levels were negatively correlated with TRPV4 expression in most tumor types from TCGA (Figure 3C). These results indicate that high copy number values and low methylation levels contribute to high TRPV4 expression in pan-cancer.

Prognostic role of TRPV4

To further evaluate the significance of TRPV4 as a prognostic marker in tumor patients, we performed univariate Cox regression analysis and Kaplan-Meier survival analysis using TCGA pan-cancer data. Results from the univariate Cox regression analysis suggested that TRPV4 was a risk factor for OS in LGG, ovarian cancer, PAAD, THYM, and UVM patients, while it was a protective factor in CESC, KICH, KIRC, and KIRP (Figure 4A). Kaplan-Meier survival analysis revealed that high TRPV4 expression predicted poorer OS in patients with ACC, HNSC, KIRP, LIHC, LUAD, and UVM and better OS in patients with KIRC and KIRP (Figure 4B). We further conducted DFI, PFI, and DSS assessments using univariate Cox regression analysis. For DFI, TRPV4 was a risk factor in PAAD and a protective factor in UCEC and UCS (Supplementary Figure 1A). For PFI, TRPV4 was a risk factor in COAD, LGG, PAAD, and UVM and a protective factor in KICH, KIRC, KIRP, and UCEC (Supplementary Figure 1B). For DSS, TRPV4 was a risk factor in COAD, GBM, LGG, LUSC, ovarian cancer, PAAD, THYM, and UVM and a protective factor in CESC, KICH, KIRC, KIRP, and LUSC (Supplementary Fig. 1C).

GSEA of TRPV4

GSEA based on the Reactome pathway database was used to predict pathways in which TRPV4 may be involved in pan-cancer. The GSEA results revealed that TRPV4 participates in immune regulation-related pathways in pan-cancer such as immunoregulatory interactions between lymphoid and non-lymphoid cells, the adaptive immune system, and the innate immune system (Figure 5A-F).

TIME analysis

Having predicted that TRPV4 is closely related to immune regulation pathways through GSEA analysis, we focused on the infiltration of immune cells in the tumor microenvironment. We found that TRPV4 expression was positively correlated with the infiltration level of TAMs and tumor associated fibroblasts (CAFs) in pan-cancer using the TIMER2 database (Figure 6A). To validate this result, we downloaded immune cell infiltration data from the ImmuCellAI database and performed a correlation analysis, obtaining the same result that TRPV4 expression was positively correlated with the level of TAMs in pan-cancer (Figure 6B).

Next, we explored the correlation between TRPV4 with immune checkpoints, immunosuppressive genes, chemokines, and chemokine receptors. Immune checkpoint and immunosuppressive genes such as PD-L1, PD-1, CTLA4, LAG3, TIGIT, TGFB1, and TGFBR1 were positively correlated with TRPV4 in most tumors (Figure 7A). Chemokines and chemokine receptors such as CCL5, CCL5, CCR4, and CCR5 were also positively correlated with TRPV4 expression in most tumors (Figure 7B-C).

Drug resistance analysis

We downloaded the IC₅₀ values of anti-cancer drugs and gene expression profiles in the relative cell lines from the GDSC database. To explore the influence of TRPV4 expression on the sensitivity of anti-cancer drugs, we divided the tumor cells into high- and low-TRPV4 groups and compared their IC₅₀ values. We found that the IC₅₀ values of several anti-cancer drugs decreased in the high-TRPV4 group, including sapitinib (an EGFR inhibitor) and selumetinib (a MEK1/2 inhibitor) (Figure 8A), indicating that patients exhibiting high TRPV4 expression levels are relatively sensitive to these anti-cancer drugs. In comparison, the IC₅₀ values of platinum drugs such as cisplatin and oxaliplatin increased in the high-TRPV4 group (Figure 8A-C). Moreover, the IC₅₀ values of cisplatin and oxaliplatin were positively correlated with TRPV4 expression (Figure 8D-E). These results indicate that patients exhibiting high TRPV4 expression levels may be resistant to cisplatin and oxaliplatin treatment.

TRPV4 is an omnipresent polymodally activated ion channel. Recent studies have shown that TRPV4 plays a role in a number of different functions in the body, including cancer. Moreover, the functions of TRPV4 are different or even opposite in different tumors. TRPV4 plays an oncogenic role in breast cancer, endometrial cancer, gastric cancer, oral squamous cell carcinoma, and COAD [2, 9-12] and a suppressor gene role in glioma[1]. However—in many other tumor types—the function of TRPV4 remains unclear.

We first assessed TRPV4 expression using tumor tissue data from TCGA and normal tissue data from TCGA and the GTEx database. We found that TRPV4 was overexpressed in 19 cancer types, namely, BLCA, CESC, CHOL, COAD, DLBCL, ESCA, GBM, LAML, LGG, LUAD, LUSC, ovarian cancer, PAAD, READ, STAD, TGCT, THYM, UCEC, and UCS. In contrast, low TRPV4 expression was observed in only six cancer types, namely, ACC, KIRP, LIHC, PRAD, SKCM, and THCA. In COAD and ovarian cancer, TRPV4 was over-expressed; moreover, high expression levels of TRPV4 predicted worse OS in tumor patients. It has been reported that TRPV4 promotes the progression of COAD[12], while no reports on TRPV4 in ovarian cancer are available.

Tumor-acclimatized immune and stromal cells in the tumor microenvironment such as TAMs and CAFs play a vital role in accelerating tumor progression. The remodeling of immune cells by tumor cells can lead to immune escape[13]. In our study, we predicted that TRPV4 is involved in immune regulation-related pathways using GSEA. Moreover, we proved that TRPV4 expression was positively correlated with TAMs and CAFs using two different methods: the TIMER2 and ImmuCellAI databases. Our results revealed that TRPV4 regulates the infiltration levels of TAMs and CAFs either directly or indirectly. Based on these results, we further explored the correlation between TRPV4 and immune checkpoints, immunosuppressive genes, chemokines, and chemokine receptors. Immune checkpoint and immunosuppressive genes such as PD-L1, PD-1, CTLA4, LAG3, TIGIT, TGFB1, and TGFBR1 were positively correlated with TRPV4 in most tumors. Chemokines and chemokine receptors such as CCL5, CCL5, CCR4, and CCR5 were also positively correlated with TRPV4 expression in most tumors. These results indicate that TRPV4 is closely associated with immune regulation. Patients with tumors exhibiting high TRPV4 expression levels may manifest an immunosuppressive status.

To explore the indicator function of TRPV4 in anti-cancer drug selection, we analyzed the association between TRPV4 expression and IC₅₀ values of anti-cancer drugs using data from the GDSC database. We found that the IC₅₀ values of several anti-cancer drugs, including sapitinib (an EGFR inhibitor) and selumetinib (a MEK1/2 inhibitor), decreased in the high-TRPV4 group, indicating that patients exhibiting high TRPV4 expression levels may be relatively sensitive to these anti-cancer drugs. In comparison, the IC₅₀ values of platinum drugs—such as cisplatin and oxaliplatin—increased in the high-TRPV4 group. Moreover, the IC₅₀ values of cisplatin and oxaliplatin were positively correlated with TRPV4 expression. These results indicate that patients exhibiting high TRPV4 expression levels may be resistant to cisplatin and oxaliplatin treatment.

We conducted a comprehensive assessment of TRPV4, revealing its potential cancer-promoting effect as well as its role as an indicator of patient prognosis. Importantly, high TRPV4 expression often indicates tumor immunosuppression, which may render immune checkpoint inhibitors unsuitable for treatment. Finally, we found that patients exhibiting high TRPV4 expression levels may be resistant to cisplatin and oxaliplatin treatment and sensitive to sapitinib (an EGFR inhibitor) and selumetinib (a MEK1/2 inhibitor) treatment. The impact of TRPV4 on the progression of numerous cancers requires a comprehensive understanding of its role as a biomarker for patient prognosis based on its broad influence on anti-cancer drug efficacy.

BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CNA, Copy number alteration; COAD, Colon adenocarcinoma; DFI, Disease-free interval; DLBCL, Diffuse large B-cell lymphoma; DSS, Disease-specific survival; ESCA, Esophageal carcinoma; GDSC, Genomics of Drug Sensitivity in Cancer; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; LGG, Low-grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; OS, Overall survival; PFI, Progression-free interval; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TAM, Tumor-associated macrophage; TCGA, The Cancer Genome Atlas; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma.

Acknowledgments

We thank Dr. Liu Chen Dong and Liang Xia for providing the database information and bioinformatic analysis.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding Statement

This study was supported by the Science and Technology Bureau of Zhejiang Province (Grant No. LGF19H160019), Taizhou Science and Technology Project, Zhejiang Province (1802KY10、1902ky29), and the Scientific Innovation Foundation of Taizhou Hospital of Zhejiang Province (18EZZDC7、15EZD15).

Author contributions

CXD, FXJ and WK conceived the project and participated in the study design and interpretation of the results. WK wrote the manuscript. CXD,ZLZ and YJH participated in the study design and helped draft the manuscript. CZY ,YXX and LXD participated in data interpretation and provided a critical review of the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Informed consent was obtained from all individual participants for whom identifying information was included in this article.

Consent for publication

All the authors report no disclosures relevant to the manuscript.

Data availability statements

The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Huang T, Xu T, Wang Y, Zhou Y, Yu D, Wang Z, He L, Chen Z, Zhang Y, Davidson D et al: Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4. AUTOPHAGY 2021:1-15.
Li X, Cheng Y, Wang Z, Zhou J, Jia Y, He X, Zhao L, Dong Y, Fan Y, Yang X et al: Calcium and TRPV4 promote metastasis by regulating cytoskeleton through the RhoA/ROCK1 pathway in endometrial cancer. CELL DEATH DIS 2020, 11(11):1009.
Li R, Liu Y, Yin R, Yin L, Li K, Sun C, Zhou Z, Li P, Tong R, Xue J et al: The Dynamic alternation of Local and Systemic Tumor Immune Microenvironment during Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial. Int J Radiat Oncol Biol Phys 2021.
Hubert P, Roncarati P, Demoulin S, Pilard C, Ancion M, Reynders C, Lerho T, Bruyere D, Lebeau A, Radermecker C et al: Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. J IMMUNOTHER CANCER 2021, 9(3).
Liu C, Zhou X, Long Q, Zeng H, Sun Q, Chen Y, Wu D, Liu L: Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene. ONCOGENE 2021, 40(2):233-245.
Deng XX, Jiao YN, Hao HF, Xue D, Bai CC, Han SY: Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways. J ETHNOPHARMACOL 2021:113978.
Gill CM, D'Andrea MR, Tomita S, Suhner J, Umphlett M, Zakashansky K, Blank SV, Tsankova N, Shrivastava RK, Fowkes M et al: Tumor immune microenvironment in brain metastases from gynecologic malignancies. Cancer Immunol Immunother 2021.
Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A et al: Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. CANCER CELL 2021.
Azimi I, Robitaille M, Armitage K, So CL, Milevskiy M, Northwood K, Lim HF, Thompson EW, Roberts-Thomson SJ, Monteith GR: Activation of the Ion Channel TRPV4 Induces Epithelial to Mesenchymal Transition in Breast Cancer Cells. INT J MOL SCI 2020, 21(24).
Wang H, Zhang B, Wang X, Mao J, Li W, Sun Y, Yuan Y, Ben Q, Hua L, Qian A: TRPV4 Overexpression Promotes Metastasis Through Epithelial-Mesenchymal Transition in Gastric Cancer and Correlates with Poor Prognosis. Onco Targets Ther 2020, 13:8383-8394.
Fujii S, Tajiri Y, Hasegawa K, Matsumoto S, Yoshimoto RU, Wada H, Kishida S, Kido MA, Yoshikawa H, Ozeki S et al: The TRPV4-AKT axis promotes oral squamous cell carcinoma cell proliferation via CaMKII activation. LAB INVEST 2020, 100(2):311-323.
Arbabian A, Iftinca M, Altier C, Singh PP, Isambert H, Coscoy S: Mutations in calmodulin-binding domains of TRPV4/6 channels confer invasive properties to colon adenocarcinoma cells. Channels (Austin) 2020, 14(1):101-109.
Komohara Y, Takeya M: CAFs and TAMs: maestros of the tumour microenvironment. J PATHOL 2017, 241(3):313-315.

Download PDF

Version 1

posted 12 Apr, 2021

You are reading this latest preprint version

TRPV4 is a Prognostic Biomarker That Correlates With the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs

Status:

Version 1

Abstract

Figures

Background

Methods

Results

Discussion

Conclusions

Abbreviations

Declarations

References

Supplementary Files

Status:

Version 1